Acetohydroxamic acid
{{Short description|Enzyme inhibitor that inhibits urease}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 477239146
| IUPAC_name = N-Hydroxyacetamide
| image = Acetohydroxamic acid.svg
| width = 125
| image2 = Acetohydroxamic-acid-3D-balls.png
| width2 = 125
| tradename = Lithostat
| Drugs.com = {{drugs.com|CDI|acetohydroxamic_acid}}
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration =
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 546-88-3
| ATC_prefix = G04
| ATC_suffix = BX03
| ATC_supplemental =
| PubChem = 1990
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00551
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 1913
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4RZ82L2GY5
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00220
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 49029
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 734
| C=2 | H=5 | N=1 | O=2
| smiles = O=C(NO)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RRUDCFGSUDOHDG-UHFFFAOYSA-N
}}
Acetohydroxamic acid (also known as AHA or by the trade name Lithostat) is a drug that is a potent and irreversible enzyme inhibitor of the urease enzyme in various bacteria and plants; it is usually used for urinary tract infections. The molecule is similar to urea but is not hydrolyzable by urease;{{cite journal | vauthors = Fishbein WN, Carbone PP | title = Urease Catalysis. Ii. Inhibition of the Enzyme by Hydroxyurea, Hydroxylamine, and Acetohydroxamic Acid | journal = The Journal of Biological Chemistry | volume = 240 | pages = 2407–14 | date = June 1965 | doi = 10.1016/S0021-9258(18)97338-2 | pmid = 14304845 | doi-access = free }} it thus disrupts the bacteria's metabolism through competitive inhibition.
Orphan drug
In 1983 the US Food and Drug Administration approved acetohydroxamic acid (AHA) as an orphan drug for "prevention of so-called struvite stones" under the newly enacted Orphan Drug Act of 1983.{{cite journal | vauthors = Marwick C | title = New drugs selectively inhibit kidney stone formation | journal = JAMA | volume = 250 | issue = 3 | pages = 321–2 | date = July 1983 | pmid = 6854890 | doi = 10.1001/jama.1983.03340030003001 }} AHA cannot be patented because it is a standard chemical compound.